Expression plasmid containing CAR nucleic acid fragment, CAR-T cell targeting CD105 containing the expression plasmid, and preparation method and application thereof
The expression plasmid of the CD105 VHH-CD8-CD137-CD3ζ fragment was constructed through CRISPR/Cas9 gene editing technology, and targeted CAR-T cells were prepared, which solved the problem of insertion mutations in the preparation of CAR-T cells in the prior art and tumor treatment. The high recurrence rate and drug resistance problem have achieved efficient targeted recognition and killing of CD105-positive tumors.
Patent Information
- Application Number
- CN202010943499.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-09-09
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2040-09-09
AI Technical Summary
The existing CAR-T cell preparation methods have problems such as insertion mutations, and traditional tumor treatment methods such as chemotherapy and radiotherapy have high recurrence rates and drug resistance problems, making it difficult to effectively target CD105-positive tumor cells.
CRISPR/Cas9 gene editing technology is used to construct an expression plasmid containing CAR nucleic acid fragments, specifically CD105 VHH-CD8-CD137-CD3ζ fragment, targeted CAR-T cells are obtained through transfection, and nano-antibody is used to improve antigen recognition ability and enhance immunity. Targeted recognition and killing activity of cells.
The efficient preparation of CD105-targeted CAR-T cells was achieved, which enhanced the specific recognition and killing ability of tumors, extended the survival time of cells in the body, and had good application prospects in tumor treatment.
Smart Images

Figure CN114231559B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of tumor biological products, and specifically relates to an expression plasmid containing a CAR nucleic acid fragment, a CD105-targeted CAR-T cell containing the expression plasmid, and a preparation method thereof and application thereof in, for example, adoptive immunotherapy. Background Art
[0002] In recent years, immunotherapy has gradually become the focus of tumor treatment, among which adoptive therapy of immune cells has become a hot topic of research. Immunotherapy based on chimeric antigen receptor modified T cells (CAR T) has been proven to be a promising cancer treatment strategy. Chimeric antigen receptor T cells extract T cells from patients and use genetic engineering technology to express receptors that recognize tumor-specific antigens on the surface of T cells. T cells bypass the antigen presentation stage and the restrictions of MHC (major histocompatibility complex) to specifically recognize and attack tumor cells. Because it is the induction and activation of autologous cells, this therapy does not have the toxic side effects of radiotherapy and chemotherapy.
[0003] CAR-T cells are composed of antigen recognition domains (ligands or single-chain antibody scFv), hinge regions, transmembrane regions, and intracellular signaling regions. The choice of target antigen is a key determinant of the specificity and effectiveness of CAR and the safety of genetically modified T cells themselves. CD105, also known as Endoglin, is a membrane antigen associated with vascular endothelial cell proliferation. It is considered to be one of the specific marker molecules of neovascular endothelial cells. It is expressed on the surface of new blood vessels and related tumor cells in solid tumors and is closely related to the prognosis of certain cancers, indicating that CD105 can be used as an attractive endothelial target. The extracellular antigen recognition region of CAR-T cells is usually a single chain variable fragment (scFv), which is composed of a heavy chain variable fragment flexibly connected to a light chain variable fragment. However, scFv is not always effectively folded and tends to aggregate. Nanobody (Nb) is composed of the variable domain of the heavy chain of HCAbs (VHH), with a small size (2.5 nm wide, 4.2 nm long), a small molecular weight (about 15KDa), can quickly diffuse throughout the body, and has good tissue penetration ability. The Nanobody gene sequence is highly homologous to the human VH gene family 3 sequence, so it has low immunogenicity in the human body. Therefore, Nanobody can be used as an ideal antigen recognition region for producing tumor antigen-specific CAR-T cells. CAR-T is mostly prepared by lentiviral transfection, which is prone to problems such as insertion mutations. CRISPR / Cas 9 technology is an emerging gene editing technology that has attracted much attention. The CRISPR / Cas 9 system consists of a non-specific Cas 9 protein and a series of fragment-specific CrRNA (CRISPR RNA). These CrRNAs can guide Cas 9 to cut DNA at the targeted location and produce double-strand breaks. The cell then repairs the broken DNA with the help of homologous recombination or non-homologous end joining mechanisms, resulting in the site-specific insertion, deletion or gene replacement of the required gene at the targeted location.
[0004] Malignant tumors have become one of the most serious diseases that endanger human health. Traditional treatments for tumors include surgery, chemotherapy, and radiotherapy. Although traditional methods can alleviate the disease, they have problems such as high tumor recurrence rate, chemotherapy resistance, and serious impact on quality of life. In recent years, comprehensive treatment has improved the therapeutic effect of tumors, but a considerable number of patients still relapse or develop resistance to conventional treatment. For this reason, we proposed an expression plasmid containing a CAR nucleic acid fragment, a CD105-targeted CAR-T cell containing the expression plasmid, a preparation method thereof, and its application in tumor treatment. Summary of the invention
[0005] In order to solve one or more technical problems in the prior art, the present invention provides, in the first aspect, an expression plasmid containing a CAR nucleic acid fragment, wherein the CAR nucleic acid fragment is a chimeric antigen receptor CD105 VHH-CD8-CD137-CD3ζ fragment, which is composed of CD105 VHH, CD8 hinge region and transmembrane region, the intracellular signaling domain of CD137 and the intracellular signaling domain of CD3ζ in series.
[0006] In a second aspect, the present invention provides an engineered CD105-targeted CAR-T cell, wherein the CAR-T cell is transfected with the expression plasmid described in the first aspect of the present invention.
[0007] The present invention provides in a third aspect a method for preparing the CAR-T cell according to the second aspect of the present invention, the method comprising the following steps:
[0008] (1) preparing the expression plasmid described in the first aspect of the present invention;
[0009] (2) A method for transfecting the expression vector into T cells to obtain CAR-T cells.
[0010] In a fourth aspect, the present invention provides use of the expression plasmid described in the first aspect of the present invention in preparing the CAR-T cells described in the second aspect of the present invention.
[0011] In a fifth aspect, the present invention provides the use of the CAR-T cells described in the second aspect of the present invention in the preparation of a preparation for treating tumors.
[0012] The researchers of the present invention found that in the immunotherapy of CD105-positive tumors, the advantages of CD105 CAR-T are specific targeting, enhanced immune cell targeted recognition of tumor antigens, chimeric antigen receptor-dependent tumor killing activity, and infiltration at the tumor site after infusion. These characteristics of CD105CAR-T cells originate from the functional structure of the chimeric antigen receptor, which mainly includes an antigen recognition region and a cell activation region. The intracellular activation region can prolong the survival time of cells in the body. In addition, the present invention uses the CRISPR / Cas9 gene editing method to prepare CAR-T cells, and provides a method for efficiently preparing CD105 CAR-T cells. The CAR-T prepared by this method can stably express chimeric antigen receptors and has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 :T7E1 detection shows that gRNA has targeted knockout of AAVS1 locus. Among them, lanes 1-3 are PCR products cut into 3 or more bands; lanes 4-10 are controls, with no changes.
[0014] Figure 2 : Schematic diagram of pLVX-CAR vector.
[0015] Figure 3 :Puc-Mdonor vector restriction enzyme electrophoresis. Wherein, M represents 15000bp marker; 1 represents no restriction enzyme digestion; 2 represents KpnⅠ single restriction enzyme digestion; 3 represents Hind Ⅲ single restriction enzyme digestion; 4 represents double restriction enzyme digestion.
[0016] Figure 4 : PCR identification diagram after ligation of CAR fragment with Puc-Mdonor restriction vector. M represents 15000 bp marker; 1 represents Puc-Mdonor-mock; 2 represents Puc-Mdonor-CD19 CAR; 3 represents Puc-Mdonor-CD105CAR.
[0017] Figure 5 :T cells expressed GFP fluorescence after electroporation.
[0018] Figure 6 : Expression of CAR after electroporation of T cells.
[0019] Figure 7 :CD105 CAR-T specifically kills CD105 positive tumor cells. DETAILED DESCRIPTION
[0020] As described above, the present invention provides, in the first aspect, an expression plasmid containing a CAR nucleic acid fragment, wherein the CAR nucleic acid fragment is a chimeric antigen receptor CD105 VHH-CD8-CD137-CD3ζ fragment, which is composed of CD105 VHH, CD8 hinge region and transmembrane region, the intracellular signaling domain of CD137 and the intracellular signaling domain of CD3ζ in series.
[0021] In some preferred embodiments, the CAR nucleic acid fragment is as shown in SEQ ID NO. 1; preferably, the expression plasmid is a Puc-Mdonor plasmid into which the CAR nucleic acid fragment is inserted.
[0022] In a second aspect, the present invention provides an engineered CD105-targeted CAR-T cell, wherein the CAR-T cell is transfected with the expression plasmid described in the first aspect of the present invention.
[0023] In some preferred embodiments, the CAR-T cells are further transfected with a second plasmid comprising a gRNA recognition sequence of the human AAVS1 gene. More preferably, the gRNA recognition sequence is shown in SEQ ID NO. 2. Further preferably, the second plasmid is a px330 plasmid into which the gRNA recognition sequence is inserted.
[0024] The present invention provides in a third aspect a method for preparing the CAR-T cell according to the second aspect of the present invention, the method comprising the following steps:
[0025] (1) preparing the expression plasmid described in the first aspect of the present invention;
[0026] (2) A method for transfecting the expression vector into T cells to obtain CAR-T cells.
[0027] In some preferred embodiments, the CAR nucleic acid fragment is prepared by the following method:
[0028] (I) Synthesizing chimeric antigen receptor CD105 VHH-CD8-CD137-CD3ζ nucleic acid fragments;
[0029] (II) cloning the nucleic acid fragment into the expression vector pLVX to obtain a pLVX-CAR plasmid into which the nucleic acid fragment is inserted;
[0030] (III) amplifying the nucleic acid fragment by PCR using the pLVX-CAR plasmid;
[0031] (IV) inserting the amplified nucleic acid fragment into a Puc-Mdonor vector plasmid to obtain a Puc-Mdonor-CAR plasmid into which the nucleic acid fragment is inserted.
[0032] In some more preferred embodiments, restriction endonucleases are used when inserting the amplified nucleic acid fragment into the Puc-Mdonor vector plasmid. Kpn Ⅰ / HindⅢ double-digested the Puc-Mdonor vector plasmid.
[0033] In some more specific embodiments, the expression plasmid Puc-Mdonor-CAR can be constructed by the following method: synthesize the chimeric antigen receptor CD105VHH-CD8-CD137-CD3ζ fragment, and subclone the synthesized fragment into the expression vector pLVX after EcoR I / Not I double digestion. After sequencing is correct, use the endotoxin-free Plasmid MiniKit to extract the plasmid to obtain the pLVX-CAR plasmid. Using the pLVX-CAR plasmid as a template, the target fragment is amplified by PCR, and the restriction endonuclease is used to KpnThe vector plasmid Puc-Mdonor was double-digested with Ⅰ / HindⅢ, and the digestion products were subjected to agarose gel electrophoresis and recovered by gel extraction kit. The CAR fragment and the digested Puc-Mdonor plasmid were connected using T4 DNA quick ligase, and the connection products were transferred into DH5α competent cells. After the competent cells were cultured in large quantities, the plasmid was extracted to obtain the Puc-Mdonor-CAR plasmid.
[0034] In other preferred embodiments, the method further comprises transfecting T cells with the second plasmid comprising the gRNA recognition sequence of the human AAVS1 gene, thereby obtaining CAR-T cells simultaneously transfected with the expression vector described in the first aspect of the present invention and the second plasmid.
[0035] In other preferred embodiments, when the nucleic acid fragment is cloned into the expression vector pLVX, the restriction endonuclease EcoR I / Not I is used to perform double digestion on the expression vector pLVX.
[0036] In other preferred embodiments, the gRNA recognition sequence comprising the human AAVS1 gene is synthesized by the following method:
[0037] (i) Based on the exon sequence of the human AAVS1 gene, a single-stranded gRNA recognition sequence of 19 to 23 bases was designed and synthesized according to the requirements of CRISPR / cas9 gene editing technology for sgRNA, and then the reverse complementary sequence of the recognition sequence was synthesized to obtain a double-stranded gRNA recognition sequence;
[0038] (ii) The pX330 plasmid was digested with restriction endonuclease Bbs I, and the digestion product was recovered by agarose gel electrophoresis. The double-stranded gRNA recognition sequence and the digested pX330 plasmid digestion product were ligated with T4 DNA ligase to obtain a px330-gRNA plasmid with an inserted gRNA recognition sequence.
[0039] In some more specific embodiments, the recombinant plasmid px330-gRNA is first constructed: on the exon sequence of the human AAVS1 gene, a 19-23 base sequence is designed and synthesized according to the requirements of the CRISPR / cas9 gene editing technology for sgRNA, for example, as shown in SEQID NO.8 in the sequence table, and its reverse complementary Oligo is synthesized at the same time, and double-stranded Oligo is synthesized on a PCR instrument. The pX330 plasmid is digested with restriction endonuclease Bbs I, and the digested product is subjected to agarose gel electrophoresis, and the gel is cut and recovered using a Gel Extraction Kit. The double-stranded Oligo and the digested pX330 plasmid are connected using T4 DNA quick ligase to obtain the recombinant plasmid px330-gRNA. In addition, the ligation product can be further transferred into DH5α competent cells, and the amplified plasmid px330-gRNA is extracted after the competent cells are cultured in large quantities.
[0040] In addition, the plasmid can be transfected into 293T cells, and the whole genomic DNA of the cells can be extracted using a DNA extraction kit. The genomic DNA near the gRNA target site can be amplified, and the PCR product can be digested using the T7E1 (T7 endonuclease I) method to identify the knockout efficiency.
[0041] In other preferred embodiments, the expression plasmid described in the first aspect of the present invention and the second plasmid are simultaneously transfected into T cells by the following method: activating T cells; mixing the expression plasmid and the second plasmid and adding them to an electroporation cup, electro-transfecting the expression plasmid and the second plasmid into the activated T cells under the conditions of 100 V voltage, 5 ms, and 1 capacitance, and culturing the electro-transfected activated T cells using RIPM 1640 complete medium to obtain the CAR-T cells.
[0042] In some more specific embodiments, the T cells can be activated with the easy-T kit, the activated T cells can be resuspended in the electroporation solution, and the Puc-Mdonor-CAR plasmid and the px330-gRNA plasmid can be mixed with the electroporation solution. The mixed plasmid and activated T cells are transferred to the electroporation cup, and electroporation is performed under the conditions of 100V voltage, 5ms, and 1 capacitance. After completion, the preheated RIPM1640 complete medium is quickly added and gently added to the electroporation cup, and then all the liquid in the electrode cup is sucked out and inoculated into the well plate with the preheated medium. After culturing for 4 hours, the RIPM 1640 complete medium containing 100 U / ml rhIL-2 is replaced.
[0043] In some more specific embodiments, the method includes the following steps: designing gRNA for the PPP1R12C gene at the AAVS1 site of chromosome 19, and constructing a CRISPR / Cas9 vector (px330-gRNA). The T7E1 method is used to verify whether the designed gRNA has a cutting effect. The second-generation CARs molecule containing CD105 nanoantibodies in the extracellular segment, 4-1BB as the co-stimulatory molecule, and CD3ζ as the domain is loaded into the pLVX expression vector by RT-PCR, and the sequence is sequenced to verify the correctness. The CAR fragment is obtained by PCR, and the CAR fragment is connected to the Puc-Mdonor-AAVS1 vector to construct a homologous and homologous vector Puc-Mdonor-CAR with an exogenous gene with about 1kb homologous arms at both ends. The CRISPR / Cas9 vector and the homologous recombination vector are introduced into T lymphocytes by electrotransfection, and CAR-T cells are constructed using CRISPR / Cas9 gene editing technology to make T cells express the chimeric antigen receptor.
[0044] In some preferred embodiments, T cells are prepared by isolating mononuclear cells from peripheral blood and then culturing them to obtain T cells.
[0045] In some preferred embodiments, the electroporated T cells are cultured, and when the cell amount accounts for 80-90% of the culture bottle, the cells are collected and the medium is replaced, and complete culture medium with a final concentration of 100 U / mL of IL-2 is added for expansion culture, and the infected cells are identified by flow cytometry.
[0046] In some preferred embodiments, the CAR-T cells are prepared using the CRISPR / Cas9 gene editing method.
[0047] In a fourth aspect, the present invention provides use of the expression plasmid described in the first aspect of the present invention in preparing the CAR-T cells described in the second aspect of the present invention.
[0048] The present invention provides in a fifth aspect the use of the CAR-T cells described in the second aspect of the present invention in the preparation of a preparation for treating a tumor. Preferably, the tumor is a CD105 positive tumor. More preferably, the tumor is a liver tumor. Further preferably, the tumor is a liver tumor caused by a liver cancer cell selected from the group consisting of liver cancer cells Bel7404, HepG2, SMCC7721 and MHCC97H. Example
[0049] The present invention is further described in detail below in conjunction with specific embodiments. The given examples are only for illustrating the present invention, but not for limiting the scope of the present invention.
[0050] The experimental methods in the following examples are all conventional methods unless otherwise specified.
[0051] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.
[0052] Example 1: Preparation and activation of T cells
[0053] (1) Density gradient centrifugation to separate peripheral blood T lymphocytes
[0054] Fresh peripheral blood was collected from healthy volunteers using a blood collection tube with anticoagulant. An equal volume of PBS at 37°C was mixed with the peripheral blood. Peripheral blood T lymphocytes were separated by density gradient centrifugation. 4 ml of 37°C sterile lymphocyte separation solution was pipetted into a 15 ml centrifuge tube. 8 ml of diluted peripheral blood was slowly added to the separation solution along the wall of the centrifuge tube and centrifuged at 2000 rpm for 20 min. After centrifugation, the tube was divided into four layers. The cloudy white film layer cells (PBMC) were carefully pipetted along the edge of the centrifuge tube with a Pasteur tube, and the cell suspension was collected into a sterile 50 ml centrifuge tube. Four volumes of PBS were added and the cells were washed twice. The collected PBMC cells were resuspended in complete cell culture medium RIPM 1640, transferred to a cell culture dish, and cultured in a cell culture incubator at 37°C for 2 h. The suspended cells in the cell culture dish are pipetted into another culture dish for culture. The suspended cells are T lymphocytes. The T lymphocytes are cultured with a complete RIPM1640 culture medium containing 100 U / ml rhIL-2 to obtain a mixed solution containing T lymphocytes.
[0055] (2) T cell activation
[0056] Treat the 24-well culture plate with the easy-T kit activation solution one day in advance, as follows:
[0057] 1) Add Stimu-Buffer (activation buffer) to 1xPBS at a ratio of 1:500 and mix well.
[0058] 2) Select an appropriate number of wells in a 24-well plate and add 200 μl of the mixture obtained in step 1 to each well. Tap the culture plate evenly, wrap it with sealing film, and place it at 4°C overnight.
[0059] 3) Remove the Stimu-Buffer solution before use and wash the plate once with 200 μl / well PBS.
[0060] The separated T cells were collected, resuspended in complete RIPM 1640 medium containing 100 U / ml rhIL-2, added to the treated culture plate, and cultured in a 37°C, CO2 incubator for 24 hours for later use.
[0061] Example 2: Construction of CRISPR / cas9 plasmid (px330-gRNA)
[0062] On the PPP1R12C gene at the AAVS1 site of human chromosome 19, a 19-23 base sequence was designed and synthesized according to the requirements of CRISPR / cas9 gene editing technology for sgRNA, as shown in SEQ ID NO.8 in the nucleic acid sequence table, and its reverse complementary Oligo was synthesized at the same time, and double-stranded Oligo was synthesized and annealed and phosphorylated on a PCR instrument. The pX330 plasmid was digested with restriction endonuclease Bbs I, and the digested product was subjected to agarose gel electrophoresis and recovered using a GelExtraction Kit. The double-stranded Oligo and the digested pX330 plasmid were ligated using T4 DNA quick ligase, and the ligation product was transferred into DH5α competent cells. After the competent cells were amplified and cultured, the plasmid was extracted, and the correctly identified plasmid was named px330-gRNA. The plasmid was transfected into 293T cells, and the whole genomic DNA of the cells was extracted using a DNA extraction kit. The genomic DNA near the gRNA target site was amplified, and the PCR product was digested using the T7E1 (T7 endonuclease I) method to identify the knockout efficiency. The results are shown in Figure 1 .Depend on Figure 1 It can be seen that the designed gRNA has a knockout effect on AAVS1.
[0063] Example 3 Construction of Donor vector (Puc-Mdonor-CAR)
[0064] The chimeric antigen receptor CD105 VHH-CD8-CD137-CD3ζ fragment (shown in SEQ ID NO.1, referred to as CAR fragment) was fully synthesized and subcloned into the expression vector pLVX after EcoR I / Not I double digestion. After sequencing to identify the correct clone, the plasmid was extracted using the endotoxin-free Plasmid Mini Kit and named pLVX-CAR (see Figure 2 ). Using the pLVX-CAR plasmid as a template, the target CAR fragment was amplified by PCR and restriction endonucleases were used. Kpn Ⅰ / HindⅢ double digestion The vector plasmid Puc-Mdonor was double digested with HindⅢ (see Figure 3). The digested product was subjected to agarose gel electrophoresis, and then the gel was excised and recovered using a Gel Extraction Kit. The CAR fragment and the digested Puc-Mdonor plasmid were connected using T4 DNA Quick Ligase. The ligation product was then transferred into DH5α competent cells, and the plasmid was extracted after amplification and culture of the competent cells and tested by sequencing. The plasmid with the correct sequencing was named Puc-Mdonor-CAR, and the electrophoresis diagram for PCR identification is shown in Figure 4 .
[0065] Example 4: Construction of chimeric antigen receptor modified T cells expressing CD105 nanobody (CD105 CAR-T)
[0066] (1) Transfect T lymphocytes by electroporation: Take 82 μl of the electroporation solution (Solution) and 18 μl of the supply solution in the lonza nucleofector cell electroporation kit (Lonza, Switzerland) and place them in an EP tube and mix them well to obtain a 100 μl mixed solution. Take 90 μl of the mixed solution to resuspend the activated T cells prepared in step (2) of Example 1 to obtain a T cell resuspension. Take the remaining 10 μl and add the Puc-Mdonor-CAR plasmid (4 μl) and px330-gRNA (2 μl) to obtain a plasmid mixture with a final total plasmid concentration of 1 μg / μl. After mixing the plasmid mixture and the T cell resuspension evenly, transfer them to an electroporation cup, place the electroporation cup in a 4D-Nucleofector instrument, and perform electroporation at a voltage of 100 V, 5 ms, and 1 capacitance. After transfection, RIPM 1640 complete medium preheated to 37°C was quickly added to the electroporation cup, and then all the liquid in the electrode cup was aspirated and inoculated into the well plate containing RIPM 1640 complete medium preheated to 37°C. After culturing at 37°C for 4 hours, centrifuge at 1000 rpm for 5 minutes, aspirate the supernatant and discard it, and culture with RIPM1640 complete medium containing 100 U / ml rhIL-2 for another 48 hours to obtain CD105 CAR-T cells. The expression of GFP was observed under a fluorescence microscope. The results are shown in Figure 5 .
[0067] (2) Detection of chimeric antigen receptor CD105 CAR expression in T cells using flow cytometry
[0068] Collect 1×10 6Electroporated CD105 CAR-T cells and CAR-T cells without extracellular recognition receptors (Mock) were incubated with PE-anti His tag antibody in the dark. They were then washed with PBS and detected by flow cytometry. The results showed that chimeric antigen receptors were expressed in T cells (see Figure 6 ).
[0069] Example 5: Cytotoxicity analysis of CD105 CAR-T cells killing human tumor cells
[0070] The liver cancer cells Bel7404, HepG2, SMCC7721, and MHCC97H were stained with PKH26 cell membrane dye, and then the CA105 CAR-T cells prepared in Example 4 and the activated T cells cultured in step (2) of Example 1 were respectively taken and 5×10 5 Effector T lymphocytes were added to target cells in a 24-well plate at effector-target ratios (E:T) of 1:3, 1:1, and 3:1, respectively. After culturing at 37°C for 16 hours using RIPM 1640 complete medium, effector T lymphocytes and target cells were collected, PI staining solution was added, and incubated at 4°C in the dark for 30 minutes. Centrifuge at 1200 rpm for 6 minutes in a high-speed centrifuge, remove the supernatant, and add 500 μl of PBS to resuspend the cells. PKH26 + PI + The cells were dead, and PKH26 was detected by flow cytometry. + PI + The killing rate of CAR T cells on different cells was calculated according to the following formula: Killing rate = 100% × (apoptosis rate of experimental wells - apoptosis rate of natural release wells) / (100 - apoptosis rate of natural release wells). Natural release wells are target cells without effector cells. The results are shown in Figure 7 .like Figure 7 As shown in the figure, CD105 CAR-T cells have significant specific killing activity against tumor cells with high expression of CD105.
[0071] The sequences involved in the embodiments are as follows:
[0072] (1) CD105 VHH-CD8-CD137-CD3ζ nucleotide sequence (SEQ ID NO. 1)
[0073] ATGGCCTTACCCGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGAGCCAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTCGGTGCAGGCTGGAGGGTCTCTGAGACTCTCCTGTGTAGCGTCTGGATACACAGTCAGTAGGGGCTACATGGGCTGGTTCCGCCAGGCTCCAGGGAAGGAGCGCGAGGCTGTCGCAGCTATTCGTACTGGTAGTGGTAGCACATACTATGCCGACTCCGTGAAGGGCCGATTCACCATCTCCCAAGACAATGCCAAGAACACGGTGTATCTGCAAATGAACAGCCTGAAACACGAGGACACTGGCATGTACTACTGTGCGGCATCTCTTTGGTACGGTGGTAACTGGCAATCCTGGGGGTCGTATAACTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCAGAGTCCAAATATGGTCCCCCATGCCCACCATGCCCA TTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTGCTAGTA ACAGTGGCCTTTATTATTTTCTGGGTG AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGCAGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC
[0074] (2) Sig sequence (SEQ ID NO. 2):
[0075] GCCTTACCCGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGAGC
[0076] (3) CD105Nb 184 (SEQ ID NO. 3):
[0077] CAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTCGGTGCAGGCTGGAGGGTCTCTGAGACTCTCCTGTGTAGCGTCTGGATACACAGTCAGTAGGGGCTACATGGGCTGGTTCCGCCAGGCTCCAGGGAAGGAGCGCGAGGCTGTCGCAGCTATTCGTACTGGTAGTGGTAGCACATACTATGCCGACTCCGTGAAGGGCCGATTCACCATCTCCCAAGACAATGCCAAGAACACGGTGTATCTGCAAATGAACAGCCTGAAACACGAGGACACTGGCATGTACTACTGTGCGGCATCTCTTTGGTACGGTGGTAACTGGCAATCCTGGGGGTCGTATAACTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCA
[0078] (4) CD8 hinge sequence (SEQ ID NO. 4):
[0079] GAG TCC AAA TAT GGT CCC CCA TGC CCA CCA TGC CCA
[0080] (5) CD8 TM sequence (SEQ ID NO. 5):
[0081] TTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATT ATTTTCTGGGTG
[0082] (6) CD137 sequence (SEQ ID NO. 6):
[0083] AAACGGGGCAGAAAGAAACTCCTGTATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG
[0084] (7) CD3ζ sequence (SEQ ID NO. 7):
[0085] AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGCAGAGAAGGAAGAACCCTCAGG AAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGCCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC
[0086] (8) AAVS1 gRNA sequence (SEQ ID NO. 8):
[0087] CACCGACAGAAAAGCCCCATCCTT
[0088] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the main purpose of the technical solutions of the embodiments of the present invention. SEQUENCE LISTING <110> Guangxi Medical University <120> Expression plasmid containing CAR nucleic acid fragment, CAR-T cell targeting CD105 containing the expression plasmid, and preparation method and application thereof <130> GY20100576 <160> 8 <170> PatentIn version 3.5 <210> 1 <211> 1023 <212> DNA <213> Synthetic <400> 1 atggccttac ccgtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60 ccgagccagg tgcagctgca ggagtctggg ggaggctcgg tgcaggctgg agggtctctg 120 agactctcct gtgtagcgtc tggatacaca gtcagtaggg gctacatggg ctggttccgc 180 caggctccag ggaaggagcg cgaggctgtc gcagctattc gtactggtag tggtagcaca 240 tactatgccg actccgtgaa gggccgattc accatctccc aagacaatgc caagaacacg 300 gtgtatctgc aaatgaacag cctgaaacac gaggacactg gcatgtacta ctgtgcggca 360 tctctttggt acggtggtaa ctggcaatcc tgggggtcgt ataactactg gggccagggg 420 acccaggtca ccgtctcctc agagtccaaa tatggtcccc catgcccacc atgcccattt 480 tgggtgctgg tggtggttgg tggagtcctg gcttgctata gcttgctagt aacagtggcc 540 tttattattt tctgggtgaa acggggcaga aagaaactcc tgtatatatt caaacaacca 600 tttatgagac cagtacaaac tactcaagag gaagatggct gtagctgccg atttccagaa 660 gaagaagaag gaggatgtga actgagagtg aagttcagca ggagcgcaga cgcccccgcg 720 taccagcagg gccagaacca gctctataac gagctcaatc taggacgaag agaggagtac 780 gatgttttgg acaagagacg tggccgggac cctgagatgg ggggaaagcc gcagagaagg 840 aagaaccctc aggaaggcct gtacaatgaa ctgcagaaag ataagatggc ggaggcctac 900 agtgagattg ggatgaaagg cgagcgccgg aggggcaagg ggcacgatgg cctttaccag 960 ggtctcagta cagccaccaa ggacacctac gacgcccttc acatgcaggc cctgccccct 1020 cgc 1023 <210> 2 <211> 63 <212> DNA <213> Synthetic <400> 2 gccttacccg tgaccgcctt gctcctgccg ctggccttgc tgctccacgc cgccaggccg 60 agc 63 <210> 3 <211> 375 <212> DNA <213> Synthetic <400> 3 caggtgcagc tgcaggagtc tgggggaggc tcggtgcagg ctggagggtc tctgagactc 60 tcctgtgtag cgtctggata cacagtcagt aggggctaca tgggctggtt ccgccaggct 120 ccagggaagg agcgcgaggc tgtcgcagct attcgtactg gtagtggtag cacatactat 180 gccgactccg tgaagggccg attcaccatc tcccaagaca atgccaagaa cacggtgtat 240 ctgcaaatga acagcctgaa acacgaggac actggcatgt actactgtgc ggcatctctt 300 tggtacggtg gtaactggca atcctggggg tcgtataact actggggcca ggggacccag 360 gtcaccgtct cctca 375 <210> 4 <211> 36 <212> DNA <213> Synthetic <400> 4 gagtccaaat atggtccccc atgcccacca tgccca 36 <210> 5 <211> 81 <212> DNA <213> Synthetic <400> 5 ttttgggtgc tggtggtggt tggtggagtc ctggcttgct atagcttgct agtaacagtg 60 gcctttatta ttttctgggt g 81 <210> 6 <211> 126 <212> DNA <213> Synthetic <400> 6 aaacggggca gaaagaaact cctgtatata ttcaaacaac catttatgag accagtacaa 60 actactcaag aggaagatgg ctgtagctgc cgatttccag aagaagaaga aggaggatgt 120 gaactg 126 <210> 7 <211> 339 <212> DNA <213> Synthetic <400> 7 agagtgaagt tcagcaggag cgcagacgcc cccgcgtacc agcagggcca gaaccagctc 60 tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc 120 cgggaccctg agatgggggg aaagccgcag agaaggaaga accctcagga aggcctgtac 180 aatgaactgc agaaagataa gatggcggag gcctacagtg agattgggat gaaaggcgag 240 cgccggaggg gcaaggggca cgatggcctt taccagggtc tcagtacagc caccaaggac 300 acctacgacg cccttcacat gcaggccctg ccccctcgc 339 <210> 8 <211> 24 <212> DNA <213> Homo sapiens <400> 8 caccgacaga aaagccccat cctt 24
Claims
1. An expression plasmid containing a CAR nucleic acid fragment, characterized in that: The CAR nucleic acid fragment is a chimeric antigen receptor CD105 Nb-CD8-CD137-CD3ζ fragment, which is composed of CD105 Nb, CD8 hinge region and transmembrane region, the intracellular signaling domain of CD137 and the intracellular signaling domain of CD3ζ in series; the CAR nucleic acid fragment is shown in SEQ ID NO.
1.
2. The expression plasmid according to claim 1, characterized in that The expression plasmid is a Puc-Mdonor plasmid containing the CAR nucleic acid fragment.
3. An engineered CD105-targeted CAR-T cell, characterized in that: The CAR-T cell contains the expression plasmid according to claim 1 or 2.
4. The CAR-T cell according to claim 3, characterized in that The CAR-T cells also contain a second plasmid comprising a gRNA recognition sequence of the human AAVS1 gene.
5. The CAR-T cell according to claim 4, characterized in that The gRNA recognition sequence is shown in SEQ ID NO.
2.
6. The CAR-T cell according to claim 4 or 5, characterized in that The second plasmid is a px330 plasmid containing the gRNA recognition sequence.
7. A method for preparing the CAR-T cell according to any one of claims 3 to 6, characterized in that: The method comprises the following steps: (1) preparing the expression plasmid according to claim 1 or 2; (2) A method for transfecting the expression vector into T cells to obtain CAR-T cells.
8. The method according to claim 7, characterized in that The CAR nucleic acid fragment is prepared by the following method: (I) Synthesizing chimeric antigen receptor CD105 VHH-CD8-CD137-CD3ζ nucleic acid fragments; (II) cloning the nucleic acid fragment into the expression vector pLVX to obtain a pLVX-CAR plasmid containing the nucleic acid fragment; (III) amplifying the nucleic acid fragment by PCR using the pLVX-CAR plasmid; (IV) inserting the amplified nucleic acid fragment into the Puc-Mdonor vector plasmid to obtain a Puc-Mdonor-CAR plasmid containing the nucleic acid fragment.
9. The method according to claim 8, characterized in that When the amplified nucleic acid fragment is inserted into the Puc-Mdonor vector plasmid, a restriction endonuclease Kpn Ⅰ / HindⅢ double-digested the Puc-Mdonor vector plasmid.
10. The method according to any one of claims 7 to 9, characterized in that The CAR-T cell also contains a second plasmid comprising a gRNA recognition sequence of the human AAVS1 gene, and the method further comprises additionally transfecting the T cell with the second plasmid comprising a gRNA recognition sequence of the human AAVS1 gene, thereby obtaining a CAR-T cell containing both the expression vector of claim 1 or 2 and the second plasmid.
11. The method according to claim 10, characterized in that When the nucleic acid fragment is cloned into the expression vector pLVX, the restriction endonuclease EcoR I / Not I is used to perform double digestion on the expression vector pLVX.
12. The method according to claim 10, characterized in that The gRNA recognition sequence comprising the human AAVS1 gene was synthesized by the following method: (i) Based on the exon sequence of the human AAVS1 gene, a single-stranded gRNA recognition sequence of 19 to 23 bases was designed and synthesized according to the requirements of CRISPR / cas9 gene editing technology for sgRNA, and then the reverse complementary sequence of the recognition sequence was synthesized to obtain a double-stranded gRNA recognition sequence; (ii) The pX330 plasmid was digested with restriction endonuclease Bbs I, and the digestion product was recovered by agarose gel electrophoresis. The double-stranded gRNA recognition sequence and the digested pX330 plasmid digestion product were ligated with T4 DNA ligase to obtain a px330-gRNA plasmid containing the gRNA recognition sequence.
13. The method according to claim 10, characterized in that The expression plasmid described in claim 1 or 2 and the second plasmid are simultaneously transfected into T cells by the following method: activating T cells; mixing the expression plasmid and the second plasmid and adding them to an electroporation cup, electro-transfecting the expression plasmid and the second plasmid into the activated T cells under the conditions of 100V voltage, 5ms, and 1 capacitance, and culturing the electro-transfected activated T cells using RIPM 1640 complete medium to obtain the CAR-T cells.
14. Use of the expression plasmid according to claim 1 or 2 in preparing the CAR-T cell according to any one of claims 3 to 6.
15. Use of the CAR-T cell according to any one of claims 3 to 6 in the preparation of a preparation for treating liver tumors.
16. The use according to claim 15, characterized in that The liver tumor is a CD105 positive liver tumor.
